Clinical Trials on KRAS G12C in France
Total 32 results
-
Elicio TherapeuticsRecruitingColorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12SUnited States
-
Dr.Laurent MineurMerck Serono International SA; BESPIM, CHU Nîmes (data analysis)Unknown
-
AmgenActive, not recruitingKRAS p, G12c Mutated /Advanced Metastatic NSCLCFinland, United States, Canada, Belgium, Spain, Korea, Republic of, Netherlands, United Kingdom, Australia, Denmark, Hungary, Sweden, Taiwan, Greece, Russian Federation, Switzerland, France, Italy, Japan, Poland, Brazil, Germany, Po...
-
D3 Bio (Wuxi) Co., LtdRecruitingKRAS P.G12CAustralia, Korea, Republic of, China, United States, Hong Kong
-
Intergroupe Francophone de Cancerologie ThoraciqueAmgenActive, not recruitingNsclc | KRAS P.G12CFrance
-
Novartis PharmaceuticalsActive, not recruitingLocally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutationSpain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Eli Lilly and Company; Genentech, Inc.; Kazia... and other collaboratorsRecruitingMetastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Brain | NTRK Family Gene Mutation | CDK Gene Mutation | PI3K Gene Mutation | ROS1 Gene Mutation | KRAS G12C MutationUnited States
-
AmgenActive, not recruitingKRAS p.G12C Mutant Advanced Solid TumorsUnited States, France, Canada, Spain, Belgium, Korea, Republic of, Austria, Australia, Hungary, Greece, Germany, Japan, Romania, Switzerland, Brazil, Portugal
-
xCuresCancer CommonsAvailableExpanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesMelanoma | Head and Neck Cancer | Glioblastoma | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Bowel Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Bladder Cancer | Thyroid Cancer | ERK Mutation | MAPK Gene Mutation | KRAS Activating... and other conditionsUnited States
-
University Hospital, ToulouseRecruitingIdiopathic Scoliosis | ERASFrance
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Colorectal Neoplasms | Colorectal Cancer | Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal | Non-Small Cell Lung Carcinoma | KRAS G12C Mutant Solid TumorsKorea, Republic of, Spain, Belgium, United States, France, Germany, Italy, Singapore
-
University Hospital, RouenUnknownDetection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma. (CTC-Pancreas)Pancreatic Adenocarcinoma | Circulating Tumor Cells | Circulating Tumor DNA (KRAS) | CA 19.9France
-
UNICANCERCompletedKRAS Gene Mutation | Infiltrating Urothelial CarcinomaFrance
-
Novartis PharmaceuticalsRecruitingCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of Lung | Cancer of the Lung | KRAS G12C Mutant Solid Tumors | Carcinoma, ColorectalUnited States, Japan, Australia, Germany, Italy, Spain, Canada, Denmark, Korea, Republic of, Taiwan, Belgium, Hong Kong, China, France, Singapore, Netherlands
-
Institut du Cancer de Montpellier - Val d'AurelleCompletedMetastatic Colorectal Cancer Patients With KRAS Mutated TumorsFrance
-
Gustave Roussy, Cancer Campus, Grand ParisRecruitingNon Small Cell Lung Cancer | KRAS P.G12CFrance
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
ETOP IBCSG Partners FoundationMirati Therapeutics Inc.RecruitingNSCLC Stage IV | KRAS P.G12CIreland, Italy, France, Spain, United Kingdom, Belgium
-
Central Hospital, Nancy, FranceInstitut de Cancérologie de LorraineEnrolling by invitationLung Cancer | Non Small Cell Lung Cancer | Lung Adenocarcinoma | KRAS Mutation-Related Tumors | EGFR Activating MutationFrance
-
Gustave Roussy, Cancer Campus, Grand ParisActive, not recruitingMetastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF MutationFrance
-
Hospices Civils de LyonUnknownMetastatic NRAS MelanomaFrance
-
Kura Oncology, Inc.CompletedThyroid Cancer | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | HRAS Mutant Tumor | Other Squamous Cell Carcinoma (SCC) With HRAS Mutant TumorSpain, United States, Korea, Republic of, France, Belgium, Germany, Greece, Italy, Netherlands, United Kingdom
-
European Organisation for Research and Treatment...Roche Pharma AG; AmgenTerminatedColorectal Cancer Metastatic | Liver Metastases | KRAS Wild Type Colorectal CancerFrance, Belgium, Austria, Netherlands, Spain, Switzerland
-
Verastem, Inc.AmgenRecruitingNon Small Cell Lung Cancer | KRAS Activating MutationUnited States, Spain, France, United Kingdom, Netherlands, Belgium
-
Assistance Publique - Hôpitaux de ParisGroupe Hospitalier Pitie-SalpetriereTerminatedHistory of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 InfectionFrance
-
Intergroupe Francophone de Cancerologie ThoraciqueCompletedCarcinoma, Non-Small-Cell Lung | KRAS Gene Mutation | ALK Gene Mutation | BRAF Gene MutationFrance
-
Verastem, Inc.CompletedNon Small Cell Lung Cancer | KRAS Activating MutationUnited States, Spain, France, Germany, Italy
-
National Cancer Institute (NCI)Active, not recruitingKRAS Gene Mutation | Recurrent Lung Non-Small Cell Carcinoma | Stage IV Lung Non-Small Cell Cancer AJCC v7United States
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceTerminatedHypertension | Hypertension Resistant to Conventional Therapy | Angiographically Proven Grade III Unilateral or Bilateral Atherosclerotic Renal Artery Stenosis (ARAS) Greater Than or Equal to 60 PercentFrance
-
EMD SeronoMerck KGaA, Darmstadt, GermanyCompletedN-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous MelanomaUnited States, Sweden, Australia, France, Italy, South Africa, Spain, United Kingdom, Germany, Netherlands, Israel, New Zealand, Belgium, Switzerland
-
Day One Biopharmaceuticals, Inc.RecruitingMelanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditionsUnited States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
-
RECORDATI GROUPCompletedProstate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRASBelgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more